Goldman Sachs’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History
Bought
Maintained
Sold
Other funds holding BTAL
FDCDDQ
OIA
CCA
KF
AWM
KAS
ASN
Goldman Sachs's BTAL Position: Q4 2025 in Review
Goldman Sachs sold out of AGF US Market Neutral Anti-Beta Fund (BTAL) in Q4 2025, closing a stake of 23,882 shares — an estimated $380K sold.
Goldman Sachs first reported a position in BTAL in Q4 2015 and held it in 13 quarters. The position peaked at $1.21M in Q4 2022. 81 funds tracked by Wall St. Rank hold BTAL as of Q4 2025.
- Goldman Sachs reported no remaining AGF US Market Neutral Anti-Beta Fund position as of Q4 2025 after selling out during the quarter.
- Goldman Sachs sold 23,882 AGF US Market Neutral Anti-Beta Fund shares in Q4 2025, an estimated $380K.
- Goldman Sachs first reported a position in AGF US Market Neutral Anti-Beta Fund in Q4 2015 and held it in 13 quarters.
- Goldman Sachs's AGF US Market Neutral Anti-Beta Fund position peaked at $1.21M in Q4 2022.
- 81 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q4 2025.
Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.